FOLH1 and prostate cancer: <h4>Background</h4><sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron-emission tomography/computed tomography (PET/CT) and <sup>68</sup>Ga-prostate-specific membrane antigen (<sup>68</sup>Ga-PSMA) PET/CT are widely used imaging modalities for the diagnosis and management of prostate cancer.